[go: up one dir, main page]

MX2024000230A - Inhibidores de cdk2. - Google Patents

Inhibidores de cdk2.

Info

Publication number
MX2024000230A
MX2024000230A MX2024000230A MX2024000230A MX2024000230A MX 2024000230 A MX2024000230 A MX 2024000230A MX 2024000230 A MX2024000230 A MX 2024000230A MX 2024000230 A MX2024000230 A MX 2024000230A MX 2024000230 A MX2024000230 A MX 2024000230A
Authority
MX
Mexico
Prior art keywords
cdk2 inhibitors
cdk2
inhibitors
cancer
treating
Prior art date
Application number
MX2024000230A
Other languages
English (en)
Inventor
Douglas Wilson
Joseph L Kim
Steven Mark Wenglowsky
Richard Vargas
Natasja Brooijmans
Philip D Ramsden
Emanuele Perola
Jr Neil Bifulco
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2024000230A publication Critical patent/MX2024000230A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona un compuesto representado por la Fórmula estructural (I): (ver Fórmula) (I), o una sal farmacéuticamente aceptable de esta útiles para tratar el cáncer. [En cumplimiento de disposiciones vigentes, se incluye nuevamente el texto de conformidad con la reivindicación Nº 1, aunque no aparece en el documento fuente redactado en idioma inglés, aquí descrito, y al cual me remito.] Un compuesto con la Fórmula I, (ver Fórmula) (I), o una sal farmacéuticamente aceptable de este, caracterizado porque R1 es alquilo C1-C4 opcionalmente sustituido con 1 a 4 halo; R2 es alquilo C1-C4 o Anillo A, caracterizado porque el alquilo C1-C4 está opcionalmente sustituido con 1 a 4 grupos, cada uno seleccionado independientemente de halo, CN y OH y/o 1 grupo de heteroarilo de 5 a 6 miembros que tiene de 1 a 3 heteroátomos en el anillo, cada uno seleccionado independientemente del grupo que consiste en O, S y NRd; y R3 se selecciona del grupo que consiste en H, alquilo C1-C4, cicloalquilo C3-C10 y heterociclilo de 4 a 12 miembros, caracterizado porque el alquilo C1-C4 y el cicloalquilo C3-C10 son cada uno opcionalmente sustituido con 1 a 4 Rc, caracterizado porque el heterociclilo de 4 a 12 miembros tiene 1 a 4 heteroátomos en el anillo, cada uno seleccionado independientemente del grupo que consiste en O, S y NRd y luego está opcionalmente sustituido en un carbono de anillo con 1 a 4 Rc; o R2 y R3 se toman junto con el átomo de carbono al que están unidos para formar el Anillo B, caracterizado porque el Anillo B es cicloalquilo C3-C10 o heterociclilo de 4 a 12 miembros, caracterizado porque el cicloalquilo C3-C10 es opcionalmente sustituido con 1 a 4 Rb, caracterizado porque el heterociclilo de 4 a 12 miembros tiene de 1 a 4 heteroátomos en el anillo, cada uno seleccionado independientemente del grupo que consiste en NRd, O y S y luego está opcionalmente sustituido en un carbono de anillo por 1 a 4 Rb; El Anillo A se selecciona del grupo que consiste en cicloalquilo C3-C10, fenilo, naftilo, heterociclilo de 4 a 12 miembros y heteroarilo de 4 a 12 miembros, caracterizado porque el cicloalquilo C3-C10, fenilo y naftilo son cada uno opcionalmente sustituido con 1 a 4 Ra, caracterizado porque el heterociclilo de 4 a 12 miembros y el heteroarilo de 4 a 12 miembros tienen 1 a 4 heteroátomos en el anillo, cada uno seleccionado independientemente del grupo que consiste en O, S y NRd y luego están opcionalmente sustituidos en un anillo de carbono con 1 a 4 Ra; Cada Ra se selecciona independientemente del grupo que consiste en halo, OH, CN, alquilo C1-C4 y alcoxi C1-C4, o dos Ra, unidos al mismo átomo, forman un =O, caracterizado porque el alquilo C1-C4 y alcoxi C1-C4 están cada uno opcionalmente sustituido con 1 a 4 grupos seleccionados cada uno independientemente del grupo que consiste en halo, OH y CN; Cada Rb se selecciona independientemente del grupo que consiste en halo, OH, CN, alquilo C1-C4 y alcoxi C1-C4, o dos Rb, unidos al mismo átomo, forman un =O, caracterizado porque el alquilo C1-C4 y alcoxi C1-C4 están cada uno opcionalmente sustituido con 1 a 4 grupos seleccionados cada uno independientemente del grupo que consiste en halo, OH y CN; Cada Rc se selecciona independientemente del grupo que consiste en halo, OH, CN, alquilo C1-C4 y alcoxi C1-C4, o dos Rc, unidos al mismo átomo, forman un =O, caracterizado porque el alquilo C1-C4 y alcoxi C1-C4 están cada uno opcionalmente sustituido con 1 a 4 grupos seleccionados cada uno independientemente del grupo que consiste en halo, OH y CN; o Cada Rd es independientemente H o alquilo C1-C6; R4 es H o alquilo C1-C4 opcionalmente sustituido con 1 a 4 grupos seleccionados cada uno independientemente de halo y OH; y R5 se selecciona del grupo que consiste en H, halo, CN y alquilo C1-C4, caracterizado porque el alquilo C1-C4 está opcionalmente sustituido con 1 a 4 grupos seleccionados cada uno independientemente de halo y OH. Es traducción fiel y completa al idioma Español del documento fuente redactado en idioma Inglés, que tuve a la vista, al cual me remito. La traducción se compone de doscientas doce (212) páginas. En la Ciudad Autónoma de Buenos Aires, a los cinco días del mes de julio del año dos mil veintidós.
MX2024000230A 2021-06-28 2022-06-27 Inhibidores de cdk2. MX2024000230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163215901P 2021-06-28 2021-06-28
PCT/US2022/035122 WO2023278326A1 (en) 2021-06-28 2022-06-27 Cdk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2024000230A true MX2024000230A (es) 2024-04-01

Family

ID=82655170

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000230A MX2024000230A (es) 2021-06-28 2022-06-27 Inhibidores de cdk2.

Country Status (19)

Country Link
US (2) US11932648B2 (es)
EP (1) EP4363423A1 (es)
JP (1) JP2024524373A (es)
KR (1) KR20240046167A (es)
CN (1) CN117897384A (es)
AR (1) AR126251A1 (es)
AU (1) AU2022301047A1 (es)
CA (1) CA3223223A1 (es)
CL (1) CL2023003965A1 (es)
CO (1) CO2024000237A2 (es)
CR (1) CR20230598A (es)
DO (1) DOP2023000280A (es)
EC (1) ECSP24006831A (es)
IL (1) IL309118A (es)
MX (1) MX2024000230A (es)
PE (1) PE20250123A1 (es)
TW (1) TW202317574A (es)
UY (1) UY39832A (es)
WO (1) WO2023278326A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
IL309118A (en) * 2021-06-28 2024-02-01 Blueprint Medicines Corp CDK2 inhibitors
AU2023393410A1 (en) 2022-12-16 2025-07-31 Astrazeneca Ab 2,6,9-trisubstituted purines
JP2026501699A (ja) * 2023-01-04 2026-01-16 ブループリント メディシンズ コーポレイション Cdk2阻害剤
JP2026501701A (ja) * 2023-01-04 2026-01-16 ブループリント メディシンズ コーポレイション Cdk2阻害剤の固体形態
JP2026501702A (ja) * 2023-01-04 2026-01-16 ブループリント メディシンズ コーポレイション Cdk2阻害剤
CN120835885A (zh) * 2023-01-04 2025-10-24 缆图药品公司 Cdk2抑制剂
EP4661874A1 (en) 2023-02-10 2025-12-17 Blueprint Medicines Corporation The cdk2 inhibitor blu-222 for treatment of cancer
UY40638A (es) 2023-02-17 2024-08-30 Novartis Ag Inhibidores de quinasa dependientes de ciclina (cdk2)
WO2025188779A1 (en) 2024-03-04 2025-09-12 Blueprint Medicines Corporation Cdk2 inhibitors for treatment of cancer
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003468A3 (cs) 2000-08-31 2004-05-12 Pfizeráproductsáinc Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy
ES2242771T5 (es) 2000-09-15 2011-10-14 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como inhibidores de proteína quinasas.
CN102250071A (zh) 2000-12-21 2011-11-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
EP1706400A1 (en) 2004-01-09 2006-10-04 Novartis AG Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
US8362031B2 (en) 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
AU2006283592A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
KR20120063283A (ko) 2010-12-07 2012-06-15 제일약품주식회사 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2014181137A1 (en) 2013-05-10 2014-11-13 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
CN105814057B (zh) 2013-07-31 2019-05-03 默克专利有限公司 用作btk抑制剂的嘧啶、吡啶和吡嗪及其用途
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
SI3302448T1 (sl) 2015-06-04 2024-03-29 Aurigene Oncology Limited Substituirani heterociklični derivati kot inhibitorji cdk
US11459308B2 (en) 2016-12-05 2022-10-04 Microbiotix, Inc. Broad spectrum inhibitors of filoviruses
EP3768680A1 (en) 2018-03-21 2021-01-27 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
TWI740288B (zh) 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
AU2019388929A1 (en) * 2018-11-30 2021-07-22 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
MY210283A (en) 2019-01-31 2025-09-08 Pfizer 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
CA3143525A1 (en) 2019-06-28 2020-12-30 Gb002, Inc. Heterocyclic kinase inhibitors and products and uses thereof
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2022061155A1 (en) 2020-09-17 2022-03-24 The Translational Genomics Research Institute Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
US20240261297A1 (en) 2021-05-20 2024-08-08 St. John's Cancer Institute Anti-cdk inhibitors for cancer treatment
WO2022266190A1 (en) 2021-06-16 2022-12-22 Blueprint Medicines Corporation Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
IL309118A (en) 2021-06-28 2024-02-01 Blueprint Medicines Corp CDK2 inhibitors
WO2023092088A1 (en) 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same

Also Published As

Publication number Publication date
UY39832A (es) 2023-01-31
CL2023003965A1 (es) 2024-12-06
JP2024524373A (ja) 2024-07-05
US11932648B2 (en) 2024-03-19
ECSP24006831A (es) 2024-07-31
US20240383902A1 (en) 2024-11-21
AR126251A1 (es) 2023-10-04
PE20250123A1 (es) 2025-01-16
TW202317574A (zh) 2023-05-01
CN117897384A (zh) 2024-04-16
US20230159535A1 (en) 2023-05-25
DOP2023000280A (es) 2024-03-28
CA3223223A1 (en) 2023-01-05
IL309118A (en) 2024-02-01
EP4363423A1 (en) 2024-05-08
KR20240046167A (ko) 2024-04-08
US20230322791A1 (en) 2023-10-12
WO2023278326A1 (en) 2023-01-05
CR20230598A (es) 2024-04-25
AU2022301047A1 (en) 2024-01-04
US11970498B2 (en) 2024-04-30
CO2024000237A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
PH12022551574A1 (en) Egfr inhibitors
MX2024000230A (es) Inhibidores de cdk2.
PH12021552805A1 (en) Cdk inhibitors
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MY208377A (en) Compounds
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
ZA202104112B (en) 15-pgdh inhibitor
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
MX2024012267A (es) Inhibidores de egfr
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
AR126196A1 (es) Proceso para preparar inhibidores de egfr
MX2021015418A (es) Terapia inmunooncologica.
PH12021552787A1 (en) Tetracyclic compounds as cdc7 inhibitors
WO2019217933A8 (en) Inhibitors of the ras oncoprotein, methods of making and methods of use thereof
UY39662A (es) Inhibidores de egfr
EP4397366A3 (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
EP4649947A3 (en) Methods for treating against viruses
AR132411A1 (es) Inhibidores de cdk2